PECAM1 and brain infarction: Compared with the dMCAO group, the Rg1 group exhibited improved neurobehavioral outcomes, reduced brain infarct volumes, enhanced expression of CD31, and increased numbers of BrdU+/CD31+ microvessels and glial fibrillary acidic protein- (GFAP-) positive vessels in the peri-infarct cortex.